US Broker Ratings

Avanos Medical, Inc. (AVNS) Stock Analysis: Insights into a Healthcare Device Innovator with Growth Potential

Avanos Medical, Inc. (NYSE: AVNS), headquartered in Alpharetta, Georgia, stands at the forefront of healthcare innovation, delivering a range of medical device solutions across North America and beyond. Specializing in..

Immatics N.V. (IMTX) Stock Analysis: A 95.92% Upside Opportunity in the Biotech Sector

Immatics N.V. (NASDAQ: IMTX), a biopharmaceutical firm specializing in innovative cancer treatments, is catching the eye of investors with a compelling potential upside of nearly 96%. Based in Tübingen, Germany,..

Community Health Systems, Inc. (CYH) Stock Analysis: Is a 21% Upside Worth the Risk?

Community Health Systems, Inc. (NYSE: CYH), a key player in the healthcare sector, is catching the eye of investors with its potential 21.34% upside. As a company operating a wide..

Atai Beckley N.V. (ATAI): Investor Outlook on a Biotech Innovator with 206% Upside Potential

Atai Beckley N.V. (NASDAQ: ATAI) is making waves in the biotechnology sector with its innovative approach to mental health treatment. Operating out of the Netherlands, this clinical-stage biopharmaceutical company is..

AngioDynamics, Inc. (ANGO): Investor Outlook Reveals 45% Upside Potential Amid Strong Buy Ratings

AngioDynamics, Inc. (NASDAQ: ANGO), a prominent player in the healthcare sector, is capturing investor attention with its medical technology innovations and promising market position. The company, headquartered in Latham, New..

Savara, Inc. (SVRA) Stock Analysis: A Promising Biotech with 70% Upside Potential

Savara, Inc. (SVRA), a clinical-stage biopharmaceutical company, has caught the attention of investors with its focus on rare respiratory diseases and a promising upside potential. With a market capitalization of..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: A Biotech Innovator with a 14.61% Potential Upside

Maze Therapeutics, Inc. (NASDAQ: MAZE) stands out in the biotechnology sector as a promising player in the development of precision medicines for renal, cardiovascular, and metabolic diseases. With a market..

REGENXBIO Inc. (RGNX) Stock Analysis: Exploring a Potential 121% Upside in the Biotech Sector

REGENXBIO Inc. (NASDAQ: RGNX), a burgeoning player in the biotechnology sector, is gaining attention for its innovative gene therapies and a potential upside that could intrigue investors seeking high returns...

Altimmune, Inc. (ALT) Stock Analysis: Unpacking a Potential 253% Upside in Biotech

Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical company, is emerging as a compelling opportunity for investors in the healthcare sector. Specializing in treatments for obesity, metabolic, and liver diseases, Altimmune..

Phibro Animal Health Corporation (PAHC): Investor Outlook Focused on Growth Potential and Robust Revenue Expansion

Phibro Animal Health Corporation (NASDAQ: PAHC) presents a compelling opportunity for investors with its solid presence in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. With..

Mind Medicine (MNMD) Stock Analysis: A Biotech Prospect with Over 100% Potential Upside

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a prominent player in the healthcare sector, specifically within biotechnology, has captured investor attention recently with its compelling growth narrative. Headquartered in New York,..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: A Promising 43.54% Upside Potential in Biotech Innovation

Tyra Biosciences, Inc. (NASDAQ: TYRA), a burgeoning player in the biotechnology sector, is catching the attention of investors with its promising pipeline and an impressive potential upside of 43.54%. Headquartered..

Fortrea Holdings Inc. (FTRE)

⚠️ No article content returned.

..

Autolus Therapeutics (AUTL) Stock Analysis: Exploring the 506% Potential Upside

Autolus Therapeutics plc (NASDAQ: AUTL), a UK-based biotechnology firm, has captured the attention of investors with its ambitious pursuit of cutting-edge T cell therapies for cancer and autoimmune diseases. As..

Arvinas, Inc. (ARVN): Investor Outlook on a Biotech Innovator with a 10.26% Potential Upside

Arvinas, Inc. (NASDAQ: ARVN), a pioneering biotechnology firm in the healthcare sector, is attracting attention with its innovative approach to drug development and a notable potential upside of 10.26%. Headquartered..

Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A Promising Biotech with 36% Potential Upside

Zenas BioPharma, Inc. (NASDAQ: ZBIO), a clinical-stage biopharmaceutical company specializing in immunology-based therapies, stands out in the biotechnology sector with a market capitalization of $1.88 billion. Based in Waltham, Massachusetts,..

Orthofix Medical Inc. (OFIX) Stock Analysis: Exploring a Potential 46.53% Upside for Investors

Orthofix Medical Inc. (NASDAQ: OFIX) stands out in the healthcare sector, particularly in the medical devices industry. With a market capitalization of $616.17 million, this U.S.-based company is gaining attention..

Sana Biotechnology, Inc. (SANA) Stock Analysis: A 90% Upside Potential Beckons Investors

Sana Biotechnology, Inc. (NASDAQ: SANA) is carving its niche in the rapidly evolving healthcare sector with a focus on pioneering engineered cell therapies. As a biotechnology company headquartered in Seattle,..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Exploring Its 27% Potential Upside Amidst Healthcare Innovations

Myriad Genetics, Inc. (NASDAQ: MYGN), a key player in the healthcare sector, specifically within diagnostics and research, is garnering attention from investors due to its intriguing potential upside of 27.16%...

Semler Scientific, Inc. (SMLR) Investor Outlook: Unlocking a 283.79% Potential Upside in the Medical Devices Sector

Semler Scientific, Inc. (NASDAQ: SMLR), a key player in the healthcare sector, specifically within the medical devices industry, is garnering attention for its innovative technology solutions that enhance the clinical..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds